See All Slides - tctmd.com

Slides

Presentation TCT 2014

Gender Differences in 1-Year Outcomes in Patients Treated with the Diamondback 360 Coronary Orbital Atherectomy System: Results from the ORBIT II Trial

Presenter: Christopher Kim

September 16, 2014

Presentation TCT 2014

Determinants of Left Ventricular Mass Regression in Patients with Severe Symptomatic Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation

Presenter: Adaya Weissler-Snir

September 16, 2014

Presentation TCT 2014

The Role of Right Sided Hemodynamic Parameters as Predictors of 30 Day Outcome After Transcatheter Aortic Valve Replacement: The Impact of Right Ventricular Stroke Work Index

Presenter: Rajiv Tayal

September 16, 2014

Presentation TCT 2014

Patients At High Risk Of Bleeding, A Forgotten Population In DES Trials? Insights From The Ongoing LEADERS FREE Trial

Presenter: Philip Urban

September 16, 2014

Presentation TCT 2014

Comparable outcomes on single use of clopidogrel vs_ dual antiplatelet therapy after coronary stenting in patients with acute myocardial infarction

Presenter: Jun-Hyok Oh

September 16, 2014

Presentation TCT 2014

Outcomes Following Percutaneous Reduction of Significant Mitral Regurgitation in EVEREST II High Risk Patients Who Were Symptomatic Despite Cardiac Resynchronization Therapy

Presenter: Saibal Kar

September 16, 2014

Presentation TCT 2014

Comparison of endothelialization and inflammation between thin- and thick-strut contemporary bioerodable polymer drug-eluting stents and thick-strut fully resorbable scaffolds i___

Presenter: Kazuyuki Yahagi

September 16, 2014

Presentation TCT 2014

N-terminal Pro-B-type Natriuretic Peptide Ratio Predicts Mortality After Transcatheter Aortic Valve Replacement

Presenter: Ronald Binder

September 16, 2014

Presentation TCT 2014

ABSORB Cohort B Trial: Five Year Angiographic Results Of The ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold_

Presenter: Bernard De Bruyne

September 16, 2014

Presentation TCT 2014

Two-Year Clinical Outcome of Patients With Implantation of Second-Generation Drug-Eluting Stents in the Right Coronary Ostium in the TWENTE Trial

Presenter: Ming Kai Lam

September 16, 2014

Advertisement

Slides

Gender Differences in 1-Year Outcomes in Patients Treated with the Diamondback 360 Coronary Orbital Atherectomy System: Results from the ORBIT II Trial

Determinants of Left Ventricular Mass Regression in Patients with Severe Symptomatic Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation

The Role of Right Sided Hemodynamic Parameters as Predictors of 30 Day Outcome After Transcatheter Aortic Valve Replacement: The Impact of Right Ventricular Stroke Work Index

Patients At High Risk Of Bleeding, A Forgotten Population In DES Trials? Insights From The Ongoing LEADERS FREE Trial

Comparable outcomes on single use of clopidogrel vs_ dual antiplatelet therapy after coronary stenting in patients with acute myocardial infarction

Outcomes Following Percutaneous Reduction of Significant Mitral Regurgitation in EVEREST II High Risk Patients Who Were Symptomatic Despite Cardiac Resynchronization Therapy

Comparison of endothelialization and inflammation between thin- and thick-strut contemporary bioerodable polymer drug-eluting stents and thick-strut fully resorbable scaffolds i___

N-terminal Pro-B-type Natriuretic Peptide Ratio Predicts Mortality After Transcatheter Aortic Valve Replacement

ABSORB Cohort B Trial: Five Year Angiographic Results Of The ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold_

Two-Year Clinical Outcome of Patients With Implantation of Second-Generation Drug-Eluting Stents in the Right Coronary Ostium in the TWENTE Trial

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content